BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16097588)

  • 1. [Treatment outcome of hematopoietic stem cell transplantation for multiple myeloma].
    Shimazaki C
    Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1331-6. PubMed ID: 16097588
    [No Abstract]   [Full Text] [Related]  

  • 2. A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.
    Carella AM; Beltrami G; Corsetti MT; Scalzulli P; Carella AM; Musto P
    Haematologica; 2004 Dec; 89(12):1534-6. PubMed ID: 15590410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in allogeneic transplantation for multiple myeloma.
    Gahrton G
    Eur J Haematol; 2010 Oct; 85(4):279-89. PubMed ID: 20608964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential kidney and allogeneic hematopoietic stem cell transplantation.
    Tanase AD; Sinescu I; Baston C; Tacu D; Domnisor L; Stefan L; Ranete A; Lipan L; Craciun O; Manea I; Bumbea H; Ciurea SO
    Am J Hematol; 2019 Oct; 94(10):E267-E270. PubMed ID: 31342545
    [No Abstract]   [Full Text] [Related]  

  • 5. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.
    Vesole DH; Simic A; Lazarus HM
    Bone Marrow Transplant; 2001 Oct; 28(8):725-35. PubMed ID: 11781623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma.
    Einsele H; Bamberg M; Budach W; Schmidberger H; Hess CF; Wörmann B; Meisner C; Straka C; Hebart H; Trümper L; Kröger N; Zander AR; Hegewisch-Becker S; Hossfeld DK; Schmidt H; Müller P; Schlimok G; Hertenstein B; Peest D; Metzner B; Frickhofen N; Kanz L; Bensinger WI
    Bone Marrow Transplant; 2003 Sep; 32(6):593-9. PubMed ID: 12953132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hematopoietic stem cell transplantation in multiple myeloma].
    Vela-Ojeda J; Ruiz-Esparza MA
    Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current role of allogeneic stem cell transplantation in follicular lymphoma.
    Farina L; Corradini P
    Haematologica; 2007 May; 92(5):580-2. PubMed ID: 17488679
    [No Abstract]   [Full Text] [Related]  

  • 11. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
    Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
    Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
    Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA
    Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular remission of multiple myeloma with cytoreductive autografting followed by a dose-reduced allograft.
    Fujikawa K; Nakaseko C; Cho R; Abe D; Oda K; Tanaka H; Ohwada C; Ozawa S; Takeuchi M; Sakaida E; Shimizu N; Naito M; Nishimura M; Saito Y
    Bone Marrow Transplant; 2007 Nov; 40(10):997-9. PubMed ID: 17724437
    [No Abstract]   [Full Text] [Related]  

  • 14. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
    Kröger N; Einsele H; Wolff D; Casper J; Freund M; Derigs G; Wandt H; Schäfer-Eckart K; Wittkowsky G; Schmitz N; Krüger W; Zabelina T; Renges H; Ayuk F; Krüll A; Zander A;
    Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status of hematopoietic stem cell transplantation for multiple myeloma.
    Bensinger WI
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):46-52. PubMed ID: 16163159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.
    Castagna L; Mussetti A; Devillier R; Dominietto A; Marcatti M; Milone G; Maura F; de Philippis C; Bruno B; Furst S; Blaise D; Corradini P; Montefusco V
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1549-1554. PubMed ID: 28499937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
    Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
    Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
    Rabitsch W; Prinz E; Ackermann J; Wöhrer S; Kaufmann H; Seidl S; Keil F; Kalhs P; Greinix H; Gisslinger H; Leitner G; Drach J
    Eur J Haematol; 2004 Jan; 72(1):26-31. PubMed ID: 14962259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma.
    Siddiqui M; Gertz M
    Leuk Lymphoma; 2008 Aug; 49(8):1436-51. PubMed ID: 18608872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.